ImmunoCellular Therapeutics (IMUC) 10-K2013 FY Annual report

Filed: 14 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abated, addressing, announced, Anthony, ATM, begun, Cantor, count, died, easier, entirety, expended, Fitzgerald, founder, fresh, greatly, Gringeri, Hazard, imbalance, incremental, Indemnity, inherit, instruct, ITT, leukemia, line, maker, matter, missing, modified, numerical, OfferingSM, placebo, predefined, prorated, Ratio, ready, rerun, Road, run, secondary, Square, supplemental, thought, upgrading, USPTO

Removed: Academy, accountant, achievable, achieved, achievement, achieving, acted, adjuvant, advancement, affecting, Affordable, agreeing, Albuquerque, alive, Allen, alliance, amend, Anderson, Army, array, attainment, attention, Avastin, bachelor, background, Baxter, Bender, benign, Berkeley, Bexxar, binding, biology, biotech, Boockvar, Booz, Boulevard, Brandwynne, budgeted, Burbank, call, Castle, CEO, chair, Chairwoman, chemotherapeutic, Chiron, cigarette, clearance, column, commitment, Compath, compensated, computing, Connelly, controlling, Cowell, created, creation, culminating, Culpepper, cum, delivery, demonstrated, derive, directed, disappointing, discriminate, diseased, diverse, division, earned, Elma, employ, engineering, environment, Erbitux, excluding, experimentation, expert, expression, extend, extent, factor, faculty, fellow, fellowship, Floor, focused, formation, Foundation, French, fulfilling, function, gene, Genentech, George, global, glycosylated, grantee, Hamilton, Harvard, Head, Herceptin, holder, hospital, humanized, identifying, IDM, immunizing, Immunogen, immunological, immunology, indemnified, inducted, initiating, Institut, integration, integrity, internationally, investigated, investigator, Jacqueline, joining, joint, Joseph, journal, Keith, Kirk, knowledge, Lancet, laude, leader, leadership, led, liable, licensee, literature, localized, lump, Mahaley, managed, manifest, Manish, Maryland, Mason, maximum, MBA, medicine, Mental, Mexico, Michigan, Microvision, molecule, Morrison, nasdaq, necessitate, neural, Neuroimmunology, Neurologic, Neuroscience, neurosurgery, neurosurgical, Nexell, Nominating, noted, Novavax, occurred, Ohio, owed, participated, partner, partnership, Pasteur, Peacock, periodic, personally, Peter, Pharma, pilot, planning, plasma, preceding, produced, progression, prolong, proprietorship, provisional, published, pursued, Ram, recombinant, recommend, rendered, renewal, renowned, residency, resigned, Ret, retired, Rituxan, SAB, save, Scholar, School, science, Seattle, selection, sentence, serum, served, serving, Sherie, similarly, Singh, skin, smoking, Sorbonne, spent, St, Stanford, statistically, structure, studying, suggesting, sum, supported, tolerization, tolerized, Top, training, Treasurer, trust, unenforceable, USA, vaccination, vast, Vectibix, venture, Wharton, widely, Woodland, writing, Young, Zostavax, Zvi

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IMUC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:

1.	The Company’s Annual Report on Form 10-K for the period ended December 31, 2013 (the “Annual Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.	The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 14, 2014	By:	/s/ Andrew Gengos
		Name:	Andrew Gengos
		Title:	President and Chief Executive Officer